{"schema_version":"secwatch.filing_event.v1","accession":"0000917520-23-000026","form_type":"8-K","ticker":"IART","cik":"0000917520","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.800785+00:00","generated_at":"2026-06-16T15:05:00.450972+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Integra LifeSciences Q1 revenue $380.8M, organic growth 4.6%; adj EPS $0.74 flat YoY","bullets":["Q1 revenues $380.8M, +1.1% reported, +4.6% organic vs Q1 2022.","GAAP EPS $0.29 vs $0.39 prior year; adjusted EPS $0.74 flat.","Codman Specialty Surgical $248.1M (+3.5% organic); Tissue Technologies $132.7M (+6.8% organic).","Full-year 2023 guidance reaffirmed: revenue $1,602-1,620M, adj EPS $3.43-3.51.","Initiated $150M accelerated share repurchase; amended credit facility extended to 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0000917520-23-000026","json":"https://secwatch.observer/filing/0000917520-23-000026.json","markdown":"https://secwatch.observer/filing/0000917520-23-000026.md","text":"https://secwatch.observer/filing/0000917520-23-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000026/0000917520-23-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000026/iart-20230426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T15:05:00.450972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"605c17e38d64da428c776e07bb8610d68e858253","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported the first quarter ended March 31, 2023 results: revenue $380.8 million, net income $24.2 million, EPS $0.29 per diluted share. Guidance reaffirmed.","evidence_excerpt":"Total reported revenues of $380.8 million increased 1.1% on a reported basis and increased 4.6% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 61.1%, compared to 62.1% in the first quarter of 2022. Adjusted gross margin was 67.3%, compared to 67.7% in the prior year. Adjusted EBITDA for the first quarter of 2023 was $92.3 million, or 24.2% of revenue, compared to $93.5 million million, or 24.8% of revenue, in the prior year. The Company reported GAAP net income of $24.2 million, or $0.29 per diluted share, in the first quarter of 2023, compared to a GAAP net income of $32.9 million, or $0.39 per diluted share, in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000026/0000917520-23-000026-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$380.8 million"},{"label":"Net income","value":"$24.2 million"},{"label":"EPS","value":"$0.29 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}